Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis showed that the FAS -670 A/G polymorphism was associated with the risk of autoimmune diseases (GG vs. GA: OR=1.079, 95% CI=1.004-1.160, P=0.038), especially in Caucasians (GG vs. GA: OR=1.12, 95% CI=1.03-1.23, P=0.012), Asians (G vs. A: OR=0.89, 95% CI=0.83-0.96, P=0.002), systemic lupus erythematosus (SLE) (G vs. A: OR=0.85, 95% CI=0.77-0.94, P=0.001), multiple sclerosis (MS) (GG+GA vs. AA: OR=0.83, 95% CI=0.70-0.99, P=0.043), systemic sclerosis (SSc) (GG vs. GA: OR=1.20, 95% CI=1.07-1.36, P=0.003) and Hashimoto's thyroiditis (HT) (G vs. A: OR=1.45, 95% CI=1.10-1.90, P=0.008); the FAS -1377 G/A polymorphism was associated with the risk of autoimmune diseases (A vs. G: OR=1.11, 95% CI=1.03-1.20, P=0.008), especially in Asians (A vs. G: OR=1.15, 95% CI=1.05-1.25, P=0.002) and high quality studies (A vs. G: OR=1.14, 95% CI=1.05-1.24, P=0.002).
|
31840751 |
2020 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because mutations of this receptor or its ligand lead to autoimmune disorders such as systemic lupus erythematosus (SLE) and cancers, CD95 and CD95L were initially thought to play a role in immune homeostasis and tumor elimination <i>via</i> apoptotic signaling pathways.
|
29021794 |
2017 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis demonstrates that the FAS -670 A/G, FAS -1377 G/A, and FASL -844 T/C polymorphisms are associated with susceptibility to SLE.
|
27050822 |
2016 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of Fas gene polymorphisms with systemic lupus erythematosus: a meta-analysis.
|
23065220 |
2013 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Meta-analysis of the FAS -1,377 G/A polymorphism stratified by disease showed an association between the FAS -1,377 A allele and SLE (OR = 0.783, 95 % CI = 0.613-0.997, p = 0.047).
|
23053964 |
2012 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FAS mRNA editing in Human Systemic Lupus Erythematosus.
|
21793106 |
2011 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Previous findings have suggested that FAS and FASLG polymorphisms are associated with systemic lupus erythematosus, autoimmune hepatitis, vitiligo and other autoimmune-related disorders.
|
20394629 |
2010 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, results of this study imply that Fas promoter polymorphisms might contribute to individual susceptibility to SLE and influence the anti-SSB/La autoantibody response in patients.
|
20064083 |
2010 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the pathomechanisms of RLN, male and female kidneys were transplanted from FAS deficient lupus prone (LPR) or control (FAS intact) MRL mice into either LPR or MRL recipients.
|
19946036 |
2010 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
These additional genes notably included TNFRSF6 (Fas) and IRF5, supporting previous findings of their association with SLE pathogenesis.
|
18050247 |
2007 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
|
16808908 |
2006 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore we have functionally characterized the FAS/FASL promoter polymorphisms associated with SLE in other populations and demonstrate that the activity depends on the allelic variants as well as on the haplotype.
|
16163374 |
2005 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
We therefore conclude that deficient expression of CD226 and survivin in NK T cells from active SLE is a molecular base of high sensitivity of the cells to anti-CD95-induced apoptosis.
|
15661884 |
2005 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
MRL/MpJ-Tnfrsf6(lpr) (MRL/MpJ-Fas(lpr); MRL-Fas(lpr)) mice develop a spontaneous lupus syndrome closely resembling human systemic lupus erythematosus.
|
12165544 |
2002 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Fas promoter -670A/G polymorphism was significantly associated with SLE, suggesting a possibility that Fas promoter contributes, at least in part, to the pathogenesis of SLE.
|
12064832 |
2002 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
MGD |
Anti-DNA B cells in MRL/lpr mice show altered differentiation and editing pattern.
|
12486097 |
2002 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that CD95 gene mutations play little if any role in the generation of the pool of PB in SLE patients and that mutations in the CD95 gene are rare among autoantibody-producing B cells in SLE and rheumatoid arthritis.
|
12516573 |
2002 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
We conclude that CD95 gene mutations play little if any role in the generation of the pool of PB in SLE patients and that mutations in the CD95 gene are rare among autoantibody-producing B cells in SLE and rheumatoid arthritis.
|
12516573 |
2002 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fas promoter -670A/G polymorphism was significantly associated with SLE, suggesting a possibility that Fas promoter contributes, at least in part, to the pathogenesis of SLE.
|
12064832 |
2002 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Soluble CD95 concentrations in relatives of patients with severe SLE were similar to those in relatives of patients with non-severe SLE, relatives of patients with CCLE, and controls (median (interquartile range) sCD95 concentration 0.59 (0.52-0.66) v 0.57 (0.50-0.63), 0.56 (0.51-0.71), and 0.55 (0.49-0.61) ng/ml, p=0.25, p=0.94, and p=0.17, respectively).
|
11171685 |
2001 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To confirm this finding, the Fas promoter -670 genotype was examined in a second cohort of SLE patients (n = 85).
|
11550967 |
2001 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Investigation of the -1377 polymorphism on the Apo-1/Fas promoter in systemic lupus erythematosus patients using allele-specific amplification.
|
10840834 |
2000 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The role of the Apo-1/Fas gene promoter MvaI polymorphism in RA and SLE is unclear and further substantiation in larger patient samples is needed.
|
10461479 |
1999 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CD95 mutations are associated with loss of regulation of B lymphocytes, which predisposes to systemic autoimmunity including SLE.
|
10513797 |
1999 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Screening for structural defects of the Fas gene was performed by using reverse transcriptase-polymerase chain reaction (RT-PCR)/single-strand conformation polymorphism (SSCP) analysis in 57 patients with SLE, followed by direct sequencing for the aberrantly migrating bands.
|
10402071 |
1999 |